Moore David, appointed Senior Vice President, Commercial, in August 2017, joined Novo Nordisk as Senior Vice President of Marketing in May 2017. He is the key leader for Novo Nordisk’s sales and marketing team across its diabetes, obesity, hemophilia and growth hormone portfolios. In this role, he oversees commercial operations including sales, brand strategies and initiatives to enhance the company’s growth and presence in the United States. Mr. Moore has nearly 20 years of sales, marketing and executive management experience, including extensive US and global brand management leadership in multiple therapeutic areas including metabolic and cardiovascular, specialty and rare diseases. His proven track record of successful product launches and growth initiatives, and partnerships and collaborations help Novo Nordisk bring life-enhancing medicines and innovative treatment options to patients who need them. Prior to joining Novo Nordisk, Mr. Moore served as President and Chief Commercial Officer of Cempra Pharmaceuticals, a publicly traded biotech company. Mr. Moore started his business career in 1997 at Johnson & Johnson (J&J) Ortho-McNeil Pharmaceutical in sales and sales management and then moved into a director role in managed care. He spent over 5 years in J&J product marketing and new product development last serving as Group Marketing Director for the Janssen Pharmaceutical Pain Franchise. In 2013, he left J&J to join Tranzyme Pharma, as Executive Vice President, Global Commercial Operations and Chief Business Officer. When Tranzyme merged with Ocera Therapeutics, Mr. Moore was appointed Chief Business Officer and successfully led the integration prior to joining Cempra. Mr. Moore is a part-time faculty at Duke FUQUA School of Business and Duke Integrative Medicines. He holds an MBA in marketing from Lehigh University and a bachelor’s degree in biology from Towson University. Moore David, appointed Senior Vice President, Commercial, in August 2017, joined Novo Nordisk as Senior Vice President of Marketing in May 2017. He is the key leader for Novo Nordisk’s sales and marketing team across its diabetes, obesity, hemophilia and growth hormone portfolios. In this role, he oversees commercial operations including sales, brand strategies and initiatives to enhance the company’s growth and presence in the United States. Mr. Moore has nearly 20 years of sales, marketing and executive management experience, including extensive US and global brand management leadership in multiple therapeutic areas including metabolic and cardiovascular, specialty and rare diseases. His proven track record of successful product launches and growth initiatives, and partnerships and collaborations help Novo Nordisk bring life-enhancing medicines and innovative treatment options to patients who need them. Prior to joining Novo Nordisk, Mr. Moore served as President and Chief Commercial Officer of Cempra Pharmaceuticals, a publicly traded biotech company. Mr. Moore started his business career in 1997 at Johnson & Johnson (J&J) Ortho-McNeil Pharmaceutical in sales and sales management and then moved into a director role in managed care. He spent over 5 years in J&J product marketing and new product development last serving as Group Marketing Director for the Janssen Pharmaceutical Pain Franchise. In 2013, he left J&J to join Tranzyme Pharma, as Executive Vice President, Global Commercial Operations and Chief Business Officer. When Tranzyme merged with Ocera Therapeutics, Mr. Moore was appointed Chief Business Officer and successfully led the integration prior to joining Cempra. Mr. Moore is a part-time faculty at Duke FUQUA School of Business and Duke Integrative Medicines. He holds an MBA in marketing from Lehigh University and a bachelor’s degree in biology from Towson University.

Pharmaceutical Industry